Status:
UNKNOWN
Generating Evidence on NonEpileptic, Stereotypical and Intermittent Symptoms (NESIS) in Chronic Subdural Hematomas
Lead Sponsor:
Université de Sherbrooke
Conditions:
Chronic Subdural Hematoma
Epilepsy; Seizure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Some patients with chronic subdural hematomas and transient neurological symptoms do not respond to standard antiepileptic drugs. The investigators think that some of them could have cortical depressi...
Detailed Description
Patients presenting with transient neurological symptoms in the context of subdural hemorrhage may present a diagnostic challenge. Many of these patients end up with a probable diagnosis of epilepsy (...
Eligibility Criteria
Inclusion
- Be aged ≥ 18 years
- Chronic subdural hematoma
- Transient neurological symptoms (Sensory, motor, cerebellar or speech symptoms, lasting 6 hours or less)
- Initial negative EEG
Exclusion
- Contraindications to Levetiracetam
- Psychiatric history (major depression, psychosis, risk of suicide)
- History of hypersensitivity to LEV (anaphylaxis, angioedema, skin reaction)
- Contraindications to Topiramate
- History of hypersensitivity to TPM
- Glaucoma
- Past of nephrolithiasis
- Known epilepsy or past seizure before the current subdural hemorrhage
- Actual taking of an antiepileptic drug
- Intracranial pathology not caused by subdural hematoma (intra-parenchymal hemorrhage, neoplasia)
- Pregnancy or planning to
- Inability to carry out the necessary follow-ups for the study
- Refusal of the attending physician
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT04759196
Start Date
March 1 2021
End Date
December 1 2024
Last Update
April 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 5N4